Han-Joo Kim

Han-Joo Kim is an accomplished executive in the biopharmaceutical industry, currently serving as Chief Executive Officer at IMNEWRUN and as a Member of the Board of Directors at HanAll Biopharma. Previously, Han-Joo held several key positions, including Advisor for Business & Product Development and Head of R&D Business Development & Biometrics at Yuhan Corporation, where significant licensing deals were executed, including a notable agreement with Boehringer Ingelheim. Han-Joo's extensive experience encompasses roles at Eisai US, Cognizant Technology Solutions, Novartis, Allergan, and Wyeth Research, focusing on statistical leadership and biostatistics in drug development. Han-Joo Kim earned a Ph.D. in Biostatistics with a minor in Epidemiology and an M.S. in Biostatistics from the University of Pennsylvania School of Medicine, along with a B.S. in Statistics from The George Washington University.